Deuruxolitinib

• CAT Number: I025962
• CAS Number: 1513883-39-0
• Molecular Formula: C17H10D8N6
• Molecular Weight: 314.41
• Purity: ≥95%
• Synonyms: (3R)-3-(2,2,3,3,4,4,5,5-octadeuteriocyclopentyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimiin-4-yl)pyrazol-1-yl]propanenitrile
• IUPAC Name: (3R)-3-(2,2,3,3,4,4,5,5-octadeuteriocyclopentyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile
• InChI: InChI=1S/C17H18N6/c18-7-5-15(12-3-1-2-4-12)23-10-13(9-22-23)16-14-6-8-19-17(14)21-11-20-16/h6,8-12,15H,1-5H2,(H,19,20,21)/t15-/m1/s1/i1D2,2D2,3D2,4D2
• InChIKey: HFNKQEVNSGCOJV-FBXGHSCESA-N
• SMILES: [2H]C1(C(C(C(C1([2H])[2H])([2H])[2H])([2H])[2H])[C@@H](CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3)[2H]

Deuruxolitinib（Cat No.:I025962）is a selective Janus kinase (JAK) 1 and JAK2 inhibitor developed for the treatment of inflammatory and autoimmune diseases, notably alopecia areata. By blocking JAK-mediated signaling pathways involved in cytokine activity, deuruxolitinib reduces immune system overactivation and inflammation. It is administered orally and has shown efficacy in promoting hair regrowth in clinical trials for alopecia areata. Deuruxolitinib is being explored for additional indications where dysregulated JAK-STAT signaling plays a role. Its selectivity and potency make it a promising candidate in targeted immunomodulatory therapy and dermatological research.